Christopher R. Cogle, MD
PO Box 100278
Gainesville, FL 32610-0278
TEL: (352) 273-7832
FAX: (352) 273-7849
Dr. Cogle is a physician-scientist with clinical and research expertise in the myelodysplastic syndromes, acute leukemias, and bone marrow failure syndromes. He uses blood & marrow transplantation as a treatment option for patients who need more than chemotherapy to eradicate disease. Dr. Cogle also runs a stem cell research laboratory where he dissects the mechanisms of bone marrow-derived blood vessels. His research has made significant impact in the fields of cancer and cardiology. Dr. Cogle’s overall goal is to design safer and more effective methods of treating diseases by tapping into the potential of hematopoietic stem and progenitor cells.
|MD||University of Florida||Medicine|
|Residency||University of Florida||Internal Medicine|
|Fellowship||University of Florida||Medical Oncology|
|Fellowship||Duke University||Blood & Marrow Transplantation & Stem Cell Biology|
Dr. Cogle’s research focus is on human hematopoietic stem cells and cancer initiating cells. Specifically, his laboratory is focused on the following projects:
- Defining the Hemangioblast Activity of the Human Hematopoietic Stem Cell (HSC)
This project aims to define the ability of the human hematopoietic stem cell in repairing injured blood vessels. To test this hypothesis we track blood vessel repair in immunocompromised mice transplanted with human HSC enriched from umbilical cord blood, bone marrow and mobilized peripheral blood. Additionally, we study new blood vessel growth in patients and try to determine to what extent the bone marrow is the origin.
- Defining the Pathologic Hemangioblast Activity of the Hematopoietic Stem Cell in Cancer Blood Vessel Development
This project seeks to define the ability of the hematopoietic stem cell and bone marrow in contributing to the pathologic growth of blood vessels within cancer. To test this hypothesis we analyze blood vessels growing within cancers asking to what extent they are of bone marrow origin. We have developed anti-cancer treatments based on this research.
- Bone Marrow Cell Injections for Heart Disease
This project tests the ability of bone marrow cells to repair hearts after heart attacks. The Cogle laboratory is a core laboratory for the NIH Cardiovascular Cell Therapy Research Network, testing the functional capacity of bone marrow and blood in patients who receive bone marrow injections in their hearts. In addition, new technologies are being developed to enhance the function of bone marrow cells to repair the injured hearts better.
- Defining the Hemangioblast Activity of Leukemia Stem Cells
This project aims to define how leukemias exhibit hemangioblast activity, producing not only malignant leukemic cells but also malignant endothelial cells. The significance of this project is that if leukemia demonstrates hemangioblast activity, the generated malignant endothelia may serve as a sanctuary for later relapse. This begs for an alternative approach to leukemia treatment.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Aplastic anemia
- Bone marrow transplant
- Myelodysplastic Syndromes (MDS)
- Primary aplastic anemia
- Secondary aplastic anemia
- Stem cell research
- Epidemiology of cancer
- Geospatial mapping cancer
- Oncolytic virotheapy
- Drug development
- Phase I Clinical Trials
- Clinical trials
- Personalized medicine
- Precision oncology
- Genomic profiling
Other Languages Spoken:
- Madlambayan GJ, Bartee E, Kim M, Rahman MM, Meachman A, Scott EW, McFadden G, Cogle CR. Acute ,yeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res. 2012 Feb 16 [Epub ahead of print]. (PMID 22341701).
- Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodia RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moye LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository COre Laboratory rationale. Am Heart J. 2011 Dec; 162(6): 973-80. (PMID: 22137069).
- Kirabo A, Park SO, Majumder A, Gali M, Reinhard MK, Wamsley HL, Zhao ZJ, Cogle CR, Busht KS, Keseru GM, Sayeski PP. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11): 1058-68.
- Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulous AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, GOrdon DJ, Ebert RF, Kwak M, Moye LA, Simari RD, Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction on left ventricular function: the Late TIME randomized trial. JAMA. 2011 Nov 16;306(19):2110-9. Epub 2011 Nov 14. (PMID: 22084195)
- Trujillo A, McGee C, Cogle CR.Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol. 2012; 2012:128608. Epub 2011 Sep5. (PMID: 21904549).
- Garcia-Maero G, GOre SD, Cogle CR, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clini Oncol. 2011 Jun 20; 29(18):2521-7. Epub 2011 May 16. (PMID: 21576646).
- Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011 Jun 30; 117(26):7121-5. Epub 2011 Apr 29. (PMID: 21531980).
- Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. Leukemia regrssion by vascular disruption and antiangiogenic therapy. Blood. 2010 Sep 2; 116(9):1539-47. Epub 2010 May 14. (PMID: 20472832).
- Kim M, Madlambayan GJ, Rahman MM, Smallwood SE, Meacham AM, Hosaka H, Scott EW, Cogle CR, McFadden G. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hemtopoietic stem and progenitor cells. Leukemia. 2009 Dec; 23(12):2313-7. Epub 2009 Oct 29. (PMID: 19865109).
- Madlambayan GJ, Butler JM, Hosaka H, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR. Bone marrow and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 2009 Nov 5; 114(19):4310-9. Epub 2009 Aug 28. (PMID: 19717647).
- Cogle CR, Theise ND, Fu D, Ucar D, Lee S, Guthrie SM, Lonergan J, Rybka W, Krause DS, Scott EW.Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells. 2007 Aug; 25(8):1881-7. Epub 2007 May 3. (PMID: 17478582).
- Storms RW, Green PD, Safford KM, Niedzwiecki D, Cogle CR, Colvin OM, Chao NJ, Rice HE, Smith CA. Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34. Blood. 2005 Jul 1; 106(1):95-102. Epub 2005 Mar 24. (PMID: 15790790).
- Cogle CR, Wainman DA, Jorgensen ML, Guthrie SM, Mames RN, Scott EW. Adult human hematopoietic cells provide functional hemangioblast activity. Blood. 2004 Jan 1; 103(1):133-5. Epub 2003 Sep 11. (PMID: 12969964).
- Cogle CR, Moreb JS, Leather HL, Finiewicz KJ, Khan SA, Reddy VS, Wingard JR. Busulfan, cyclophosphamide and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Am J Menatol. 2003 Jul; 73(3):169-75. (PMID: 12827653).
Please click here for a list of Dr. Cogle’s industry relationships.